Abstract. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. A number of targeted therapies have been approved for clinical use or are in clinical trials. Next generation sequencing (NGS) is widely applied in the identification of actionable genomic alterations and enables personalized cancer therapy for patients. Several multiple-gene panels are available in China for the practice of precision medicine-based cancer therapy. However, the efficiency of these panels requires evaluation. The current study investigated 23 NSCLC samples using a custom designed panel of complete coding regions of ~180 cancer driver genes (FD-180) and whole exome sequencing for control samples, obtained from white blood cell samples. The results obtained suggested that actionable mutations with available targeted therapeutic options were identified in 69.6% of cases, including 60.9% of therapeutic targets recommended by the National Comprehensive Cancer Network guidelines. Furthermore, 8.7% of patients had a gene mutation that potentially qualified them for clinical trials or associated off-label therapies. As such, the results obtained in the current study demonstrated the reliability of the targeted NGS panel and its potential use for identifying actionable gene alterations and designing personalized therapies for patients with NSCLC.
Introduction
In 2015, cancer-associated mortalities in China were estimated at 2.8 million, with 4.3 million newly identified cases, the most common of which being lung cancer (1) . Non-small cell lung cancer (NSCLC) is the most commonly histologically diagnosed lung cancer, accounting for ~85-90% of cases (2) . In the past decade, genetic and genomic profiling in NSCLC has improved considerably, and with it, the understanding of underlying molecular mechanisms of disease pathogenesis and strategies for targeted therapies (3) (4) (5) . Potential inhibition targets for 60% of NSCLC cases in the form of actionable driver alterations have been identified through molecular profiling (6) . Evidence supports the effectiveness of several of these targeted therapies, including, gefitinib [epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)], erlotinib (sensitizing EGFR mutations) and crizotinib [sensitizing ALK receptor tyrosine kinase (ALK) and ROS proto-oncogene 1 receptor tyrosine kinase fusion] (7).
Next-generation sequencing (NGS) is used in the field of genomic research and clinical applications (8) . For patients with NSCLC, targeted NGS provides improved drug target screening and additional potential avenues of treatment (9) (10) (11) (12) . Due to the ever-growing number of discovered predictive markers for therapies and the limited availability of submitted tissue samples, the long-standing 'one test-one drug' paradigm is gradually being replaced by multiplexed genotyping platforms (13) . One such platform is the FoundationOne CDx (F1CDx), which received marketing approval by the Food and Drug Administration (FDA). FICDx performs NGS-based in vitro diagnostics to detect genetic mutations in all solid tumor types and serves to identify potential beneficiaries for several FDA-approved targeted treatment options (14) . With more NGS platforms being developed, standardization of reports from various test platforms is warranted (15) .
In the present study, a total of 23 NSCLC samples, containing 21 Formalin-Fixed Paraffin-Embedded (FFPE) and two cell-free DNA (cf)DNA samples were analyzed. The coding regions of ~180 cancer driver genes were explored using The Roche Nimblegen (Roche Nimblegen, Inc.) custom-designed panel. Subsequently, the captured regions were sequenced by NGS to detect various types of mutations. Whenever available (for a total of 16 patients), the sequences were compared with exome sequences obtained from white blood cell (WBC) samples. Table I . The samples were obtained from 10 males and 13 females (median age, 62 years; age range, 31-77 years). Among these patients, there was 1 smoker and 22 non-smokers.
Materials and methods

Specimen collection.
Nucleic acid preparation. Deparaffinization of 40 µm tissue sections was performed with 100% xylene (Sigma Aldrich; Merck KGaA, Darmstadt, Germany) followed by 100% ethanol as described previously (16) . Deparaffinized samples were suspended in proteinase K-contained buffer (Thermo Fisher Scientific, Inc., Waltham, MA, USA). Following extraction using phenol-chloroform (Sigma Aldrich; Merck KGaA), DNA samples were treated with ethanol (Sigma Aldrich; Merck KGaA) precipitation and resuspended in deionized water. cfDNA blood collection tubes (Streck, Inc., Omaha, NE, USA) were used for the collection of 10 ml blood samples. Procurement of 1.2 ml of plasma from every patient was performed prior to cfDNA extraction using centrifugation twice (4˚C; 1,600 x g for 10 min). cfDNA was isolated with the QIAamp Circulating Nucleic Acid kit (Qiagen, Inc., Valencia, CA, USA) according to the manufacturer's protocol. Validation of adopted protocols for the present study was obtained from previous findings (17) . A total of 2 ml of total peripheral blood was used to process WBC DNA as a control, using a FlexiGene DNA kit (Qiagen, Inc.). Quantification of isolated DNA samples was performed using a NanoDrop spectrophotometer (Thermo-Fisher Scientific, Inc.), and by fluorimetry, which was conducted using Qubit dsDNA high-sensitivity and/or broad-range assay kits (Thermo Fisher Scientific, Inc.). tumor-associated genes (data not shown). Paired-end sequencing was performed with the Illumina X Ten or NEXT SEQ 500 sequencing instrument (Illumina, Inc.) according to the manufacturer's protocol, yielding ~150 bp short sequence reads. An average of ~15G of data was generated for each WES sample, accounting for 100-200X coverage of the entire exome. The average data for FD-180 target samples was 3G.
Configuration
Data analysis. Raw data were processed into a clean FASTQ output with flexbar (v3.3; https://github.com/seqan/flexbar) through trimming of adapter sequences and removing reads of insufficient quality (average quality score <15). Raw reads were checked for the data quality using FASTQC (v0.11.5) (https://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Plots of quality scores across all bases in reads indicated that the majority of positions exhibited a quality score Q≥20. Raw reads were subsequently trimmed for adapter contamination using Trimmomatic (v0.32; www.usadellab.org). Leading and trailing low-quality bases (<3) were removed. Reads were scanned with a four-base-wide sliding window and the following bases of reads were cut when the average quality per base dropped below 15. Reads >50 bases were selected for subsequent analysis. Paired clean reads following Trimmomatic treatment were aligned against the human genome (hg19) using Burrows-Wheelers Aligner (18) . Genome Analysis Toolkit (19) was used to do base quality score recalibration, a process in which machine learning is applied to model quality score errors empirically, and the quality scores are adjusted accordingly. Analysis of the realigned BAM files, and detection of somatic single-nucleotide variants and insertions/deletions was performed using MuTect (20) . Normal germline variants were filtered out using the Single Nucleotide Polymorphism Database (dsSNP) (21) or the Exome Aggregation Consortium (ExAC; exac.broadinstitute.org). Default parameter settings were used for all programs. In-house developed scripts were used to eliminate erroneous base calls and generate final mutations based on variant frequency (>0.5%). The frequency of variation is equal to the ratio of the depth of the variant allele to the total depth of all alleles at the locus. Remaining variants were annotated using the ExAC and InterPro database (http://www. ebi.ac.uk/interpro/). Gene ontology enrichment was analyzed on the website (www.geneontology.org), focusing on the genes which were mutated in >4 primary tumor samples.
Results
In order to explore the therapeutic relevance of FD-180 and improve the survival rate of patients with NSCLC, 2 cfDNA and 21 FFPE samples were studied to detect driver mutations in tumor DNA with (16 samples) or without matched WBC DNA as a control (mean sequencing depth, 98.96x WES). The average sequencing depth on the 180 target genes for the cfDNA and FFPE samples was 1,747.7X and 398.4X respectively. Q30 for all data was 86.4%, where Q scores are defined as a property that is logarithmically associated with the base calling error probabilities. Q30 means that the accuracy of base calling is 99.9% (22) .
Somatic variations in primary tumor. The mutational signature of NSCLC samples was dissected through inspection of the spectrum of base substitutions. All 23 samples exhibited similar point mutation spectra. Cytosine to thymine was the most frequent transversion among somatic mutations, which accounted for 45.6% in primary tumor tissues ( Fig. 1A and B) . Overall, 525 somatic mutations were detected in the 23 NSCLC samples. The primary type of mutation identified was missense mutations (82.1%; Fig. 1C and D) . Notably all the mutations reported were within the protein coding regions, as APC  ATM  ATR  AXIN2  RECQL4  RET  RNF43  RUNX1   BAP1  BLM  BMPR1A  BRCA1  SBDS  SDHA  SDHAF2  SDHB  BRCA2  BRIP1  CDC73  CDH1  SDHC  SDHD  SETBP1  SLC2A2  CDK4  CDKN1B  CDKN2A  CHEK2  SLX4  SMAD4  SMARCA4  SMARCB1  CLCN7  CYLD  DDB2  DICER1  SMARCE1  SPTA1  STK11  SUFU  EPCAM  ERCC2  ERCC3  ERCC4  TERT  TGFBR2  TP53  TP63  ERCC5  EXT1  EXT2  FANCA  TSC1  TSC2  VHL  WAS  FANCB  FANCC  FANCD2  FANCE  WRN  WT1  XPA  XPC  FANCF  FANCG  FANCI  FANCL  ABL1  ABL2  AKT1  ALK  FANCM  FH  FLCN  GALNT12  AR  ARAF  ATM  ATR  GLA  GPC3  HNF1A  MAD2L2  BRAF  BRCA1  BRCA2  CDK12  MAX  MEN1  MLH1  MLH3  CDK4  CDK6  CRKL  CDKN1A  MPL  MSH2  MSH3  MSH6  CDKN2A  CHD4  CHEK2  CSF1R  MUTYH  NBN  NF1  NF2  CTNNB1  DDR2  EGFR  ERBB2  PALB2  PHOX2B  PIK3CA  PMS1  ERBB3  ERBB4  ESR1  FANCA  PMS2  POLD1  POLE  PRF1  FANCB  FANCI  FANCL  FANCC  PRKAR1A  PRKCD  PTCH1  PTEN  FANCD2  FANCE  FANCF  FANCG  RAD50  RAD51C  RAD51D  RB1  FANCM  FBXW7  FGFR1  FGFR2  TSC1  TSC2  XRCC2  SPOP  FGFR3  FGFR4  FRK  FYN  MAPK1  MAPK3  MET  mTOR  GNA11  GNAQ  GRM3  HRAS  NF1  NOTCH1  NRAS  PDGFRA  IDH1  IDH2  KDR  KIT  PIK3CA  PIK3CD  PIK3R1  PTCH1  KRAS  LYN  MAP2K1  MAP2K2  PTEN  PTPN11  RAC1  RAF1  RET  ROS1  SMO the capturing probes used in the current study were restricted to coding sequences. Variations with >5% frequency, as reported in either the dbSNP or the ExAC database, were excluded. Mutation types and numbers were compared with the normal tissue datasets, and the median variant count among the 23 samples was 18 ( Fig. 1C and D) . The high variant count in patient 1 remains unclear. Possible causes include poor living conditions and long cancer progression time prior to diagnosis.
Implicated biological processes and molecular function.
Gene Ontology (www.geneontology.org) enrichment analysis was performed with 40 frequently mutated genes (genes which were mutated in >4 primary tumor samples). 'Peptidyl-tyrosine phosphorylation', 'peptidyl-tyrosine modification', 'phosphatidylinositol-mediated signaling', 'inositol lipid-mediated signaling' and 'protein autophosphorylation' were the top five biological process of these high frequency genes in the 23 NSCLC samples (Fig. 2A) . Notably, the molecular functions of these genes included 'protein tyrosine kinase activity', 'transmembrane receptor protein tyrosine kinase activity', 'transmembrane receptor protein kinase activity', 'phosphatidylinositol 3-kinase activity' and 'phosphatidylinositol-4,5-bisphosphate-3-kinase activity' (Fig. 2B ).
Actionable mutations with available targeted therapies.
The top 20 mutated genes in the 23 tumor samples were identified by counting the frequency of mutations in different genes in the samples (Fig. 3) . EGFR, TP53, and APC were the most conmon mutated gene with a frequency of 61, 48 and 43% respectively. Among the 23 NSCLC samples, 69.57% (16/23) of the patients carried the mutations with available matched targeted therapeutic options (Table III) . This proportion is consistent with the previous study (23) . In this study, EGFR mutations which occurred in exon 18-21 were the most common mutations carried by 14 patients. A total of 13 patients harbored the EGFR sensitizing mutations, which were recommended for first-line treatment with gefitinib, erlotinib, afatinib, dacomitinib, Icotinib or osimertinib according to the NCCN, FDA or China Food and Drug Administration (CFDA) guidelines (24) (25) (26) . One of these 13 patients harbored the acquired resistance mutation EGFR p.T790M, and was amenable to third-generation EGFR inhibitors, including osimertinib, for first-line or subsequent treatment (27) . Patient 21 carried EGFR p.746_750del and PIK3CA p.R108H mutations simultaneously (Table III) . According to previous studies, approximately 4-5% of EGFR-mutated lung cancer types with acquired resistance to EGFR-TKI therapy harbor PIK3CA mutations (28) (29) (30) . A total of 2 patients harbored a KRAS p.G12C mutation, which is a common variant in NSCLC tumors (31) . CDKN2A p.W110X was detected simultaneously with EGFR p.E746_A750del in patient 12 (Table III) .
Germline mutations with clinical implications.
A number of cancer types manifest as a result of inherited defects in key genes within the genome. These genes are a subclass among the cancer driver genes. Their function may involve tumor suppressor genes, oncogenes, genes involved in DNA repair, cell cycle control, apoptosis and angiogenesis factors (32) . In the present study, germline mutations were identified through sequencing of the WBC DNA from patients and validated with paired tumor sample sequencing for 16 patients. The cancerous germline mutations identified in the 15 patients are presented in Table IV . A total of 15/16 patients (93.8%) exhibited cancer driver gene mutations. A total of 57.1% of the mutations were previously reported in the ExAC database and were described as 'Uncertain significance or not provided' in the NCBI ClinVar database, whereas 42.9% were identified as de novo mutations.
Discussion
Several single-institution studies revealed that targeted NGS permits the detection of actionable mutations in clinical lung cancer tumor samples, enabling patient selection for genotype-based therapies (10) (11) (12) . The present study demonstrated the clinical utility of FD-180 profiling in NSCLC. A total of 69.6% (16/23) NSCLC samples in the present study were identified to harbor mutations with available matched targeted therapeutic options. Notably, 13 patients harbored actionable EGFR mutations, with treatment recommended. However, 3 patients may benefit from drug agents, which have not yet been approved for lung cancer. The available data indicating PIK3CA mutations that predict the response of solid tumors to phosphoinositide 3-kinase (PI3K) signaling pathway inhibitors, including everolimus (33) and temsirolimus (34, 35) , remain controversial. Multiple PI3K inhibitors, including BYL719, buparlisib (BKM120), taselisib (GDC0032), and GSK2636771, are under investigation in patients with PIK3CA-mutated or PTEN-mutated solid tumors (36) . KRAS p.G12C has been negatively associated with progression-free survival (37) and decreased sensitivity of EGFR-TKIs, including erlotinib and gefitinib (38, 39) . Currently, the role KRAS mutations serve in the selection of anticancer treatment remains unclear; however, clinical evidence suggests that KRAS-mutant tumors, specifically in lung adenocarcinoma, respond positively to selumetinib and trametinib (40) . A phase II randomized trial indicated that a selumetinib and docetaxel combined therapy increased overall response rates and progression free survival in patients with KRAS-mutant NSCLC compared with the placebo control group (41).
A mouse model indicated that serine/threonine kinase 11-deficient KRAS mutant NSCLC tumors were resistant to mitogen-activated protein kinase (MEK) inhibition, which may be clinically relevant (42, 43) . In a phase I dose escalation trial with the MEK inhibitor trametinib, reductions in tumor size of 6-52% were observed in 8/22 patients with KRAS Somatic mutations of CDKN2A are present in various tumor types (45) (46) (47) . However, currently there are no existing standard therapy options to treat tumors harboring somatic CDKN2A alterations. The loss of function mutation of CDKN2A leads to activation of CDK2/4/6, suggesting that CDK inhibitors may be beneficial for these patients (48) . Palbociclib is a highly selective CDK4/6 inhibitor, which has demonstrated sensitivity in in vitro studies of renal cell carcinoma (49) , melanoma (50) , ovarian cancer (51) and breast cancer (52) cell lines, suggesting that this drug may be effective for the treatment of patients included in the present study.
Even though actionable genomic alterations are primarily somatically acquired, it has been reported that inherited cancer predisposition is predominantly associated with germline mutations (32) . In this study a total of 93.8% of patients (15/16) carried germline mutations which have been previously associated with cancer. Among these 28 mutations, known and de novo germline mutations were identified in 57.1% (16/28) and 42.9% (12/28), respectively. Only a small proportion of NSCLC cases may be attributed to inheritance of genetic mutations (53) . However, the results obtained in the present study suggested otherwise, indicating that the association between the identified mutations and lung cancer requires further investigation with a larger sample size.
Notably, the current study does not provide information on the long-term impact of the FD-180 gene panel on treatment outcomes, including morbidity, quality of life, disease-free survival and overall mortality. A limitation of the present study is therefore the lack of long-term follow-up to monitor these parameters. In conclusion, the present study demonstrated that the FD-180 gene panel is a robust diagnostic tool which may be used to identify targeted therapeutics for patients with NSCLC.
